Table 2.
Medications used in this study.
Medications | Total (n) | Group C | Group S |
---|---|---|---|
SGLT2i (n = 28) | |||
Empagliflozin | 12 | – | 12 |
Ipragliflozin | 5 | – | 5 |
Luseogliflozin | 5 | – | 5 |
Canagliflozin | 3 | – | 3 |
Tofogliflozin | 3 | – | 3 |
ARB (n = 26) | |||
Telmisartan | 9 | 3 | 6 |
Olmesartan | 7 | 4 | 3 |
Candesartan | 5 | 3 | 2 |
Valsartan | 3 | 1 | 2 |
Irbesartan | 2 | 2 | 0 |
ACEI (n = 2) | |||
Enarapril | 2 | 1 | 1 |
SGLT2i sodium-glucose cotransporter 2 inhibitor, ARB angiotensin II type1 receptor blocker, ACEI angiotensin converting enzyme inhibitor.